Lipodystrophy and metabolic complications of highly active antiretroviral therapy

摘要

Objective To assess the metabolic drug toxicities of first-line, World Health Organization (WHO)-recommended generic highly active antiretroviral therapy (HAART) regimens, to estimate the prevalence of body fat redistribution and to identify associated risk factors.